


**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messenger
Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Albert L. Ferro
Donald R. Banowitz
Peter A. Jackman
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Brian J. Del Buono
Virgil Lee Beason
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Rae Lynn P. Guest
Daniel A. Klein

Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Aric W. Ledford
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gabry L. Longworth
Lori A. Gordon
Nicole D. Dretar
Ted J. Ebersole
Laura A. Vogel
Michael J. Mancuso
Bryan S. Wade
Aaron L. Schwartz

Shannon A. Carroll*
Wesley W. Jones*
Matthew E. Kelley*
Michelle K. Holoubek*
Marsha A. Rose*

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee

Scott M. Woodhouse
Christopher J. Walsh
Liliana Di Nola-Baron
Peter A. Socarras
Jeffrey Mills

Of Counsel
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

March 21, 2006

WRITER'S DIRECT NUMBER:
(202) 772-8575
INTERNET ADDRESS:
MMUKHERJ@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1644

Mail Stop Amendment

Re: U.S. Utility Patent Application
Application No. 09/350,401; Filed: July 8, 1999
For: **Inducing Cellular Immune Responses to Hepatitis B Virus Using
Peptide and Nucleic Acid Compositions**
Inventors: SETTE *et al.*
Our Ref: 2473.0060008/PAJ/M-M

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Credit Card Payment Form (PTO-2038) in the amount of \$180.00 to cover IDS filing fee;
2. Request for Change of Attorney Docket Number Pleading;
3. Sixth Supplemental Information Disclosure Statement;
4. PTO/SB/08B one (1) page listing cited documents NPL0-NPL8;
5. Copies of cited documents NPL0-NPL8; and
6. A return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
March 21, 2006
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in dark ink, appearing to read 'Mita Mukherjee', with a long horizontal flourish extending to the right.

Mita Mukherjee
Agent for Applicants
Registration No. 54,325

MM/CLD/tts:awt
Enclosures

509811v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of:

Sette *et al.*

Application No.: 09/350,401

Filed: July 8, 1999

For: **Inducing Cellular Immune
Responses to Hepatitis B Virus
Using Peptide and Nucleic Acid
Compositions**



Confirmation No.: 8008

Art Unit: 1644

Examiner: Schwadron, R.

Atty. Docket: 2473.0060008/PAJ/M-M

Request for Change of Attorney Docket Number Pleading

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants respectfully request that the attorney docket number for the above-captioned application be changed from "18623-013910" to -- 2473.0060008/PAJ/M-M --. Kindly use this attorney docket number in any future correspondence addressed to the undersigned.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Mita Mukherjee
Agent for Applicants
Registration No. 54,325

Date: March 21, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
508820v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of:

Sette *et al.*

Appl. No.: 09/350,401

Filed: July 8, 1999

For: **Inducing Cellular Immune
Responses to Hepatitis B Virus
Using Peptide and Nucleic Acid
Compositions**



Confirmation No.: 8008

Art Unit: 1644

Examiner: SCHWADRON, Ronald B.

Atty. Docket: 2473.0060008/PAJ/M-M

Sixth Supplemental Information Disclosure Statement

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450
Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

03/22/2006 STENDIE1 00000112 09350401
01 FC:1806 180.00 OP

Sette *et al.*
Appl. No. 09/350,401

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Mita Mukherjee
Agent for Applicants
Registration No. 54,325

Date: March 21, 2006
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



Substitute for form 1449/PTO

SIXTH SUPPLEMENTAL INFORMATION BY APPLICANT
(Use as many sheets as necessary)

Sheet	1	of	1
Application Number	09/350,401		
§ 371 Date	July 08, 1999		
First Named Inventor	Alessandro Sette		
Art Unit	1644		
Examiner Name	Schwadron, R.		
Attorney Docket Number	2473.0060008/PAJ/M-M		

Complete if Known

Examiner	Cite No. ¹	Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
	NPL0		Bertolotti, A. <i>et al.</i> , "Cytotoxic T Lymphocyte Response to a Wild Type Hepatitis B Virus Epitope in Patients Chronically Infected by Variant Viruses Carrying Substitutions within the Epitope," <i>J. Exp. Med.</i> , 180: 933-943 (September 1994).	
	NPL1		Bowie, J.U. <i>et al.</i> , "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> , 247: 1306-1310 (March 1990).	
	NPL2		Hosono, S. <i>et al.</i> , "Core Antigen Mutations of Human Hepatitis B Virus in Hepatomas Accumulate in MHC Class II-Restricted T cell Epitopes," <i>Virology</i> , 212: 151-162 (September 1995).	
	NPL3		Kast, W.M. <i>et al.</i> , "Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins," <i>Journal of Immunology</i> , 152: 3904-12 (April 1994).	
	NPL4		Menne, S. <i>et al.</i> , "Characterization of T-cell response to Woodchuck Hepatitis Virus Core Protein and Protection of Woodchucks from Infection by Immunization with Peptides Containing a T-cell Epitope," <i>Journal of Virology</i> , 71: 65-74 (Jan 1997).	
	NPL5		Piniella, C. <i>et al.</i> , "Functional Importance of Amino Acid Residues Making Up Peptide Antigenic Determinants," <i>Molecular Immunology</i> , 30: 577-585 (April 1993).	
	NPL6		Riftkin, M.C. <i>et al.</i> , "A Single Amino-Acid Change Between the Antigenically Different Extracellular Serine Proteases V2 and B2 from Dichelobacter Nodosus," <i>Gene</i> , 167: 279-283 (December 1995).	
	NPL7		Sarobe, P. <i>et al.</i> , "Enhanced In Vitro Potency and In Vivo Immunogenicity of CTL Epitope from Hepatitis C Virus Core Protein Following Amino Acid Replacement at Secondary HLA-A2.1 Binding Positions," <i>Journal of Clinical Investigation</i> , 102: 1239-48 (September 1998).	
	NPL8		GenPept Accession AAA46769, core protein, NCBI printout, May 4, 1994.	

508728v1

Examiner	Signature	Date	Considered
----------	-----------	------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional).
² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.